OBIOOrchestra BioMed Holdings, Inc.
Price
+110%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality shaky, a flag to check, growth steady, the market with it.
Charts
As reported to the SEC, without any scoring.
Orchestra BioMed Holdings, Inc. (OBIO) reported revenue of $88K in Q2 2026 (quarter ended Jun 30, 2026), down 89% from the same quarter a year earlier. That came with a gross margin of 72% and net loss of $24M. For the full year FY2025, revenue was $33M (+1169% year on year) and net income −$53M.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 1, 2026On October 1, 2026, the Company announced that, as of September 30, 2026, 330 patients had been randomized in the BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”), exceeding its previously announced target of 316 randomized patients.Regulation FD disclosure · Form 8-K
- Sep 8, 2026Accelerating high - impact technologies to patients through risk - reward sharing partnerships Corporate Overview | September 2026 Nasdaq: OBIO.Regulation FD disclosure · press release
- Feb 13, 2026Cash Bonus Plan On February 12, 2026, the Board of Directors (the “Board”) of Orchestra BioMed Holdings, Inc. (the “Company”), upon the recommendation of the Compensation Committee of the Board (the “Compensation Committee”), approved the 2026 cash bonus plan for all executive officers (the “Plan”), which: · …Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.